REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...
Earnings call Codexis reported Q3 2025 revenue of $8.6M, down 33% YoY, but improved gross margins to 64% from 61%. Backed by a Merck agreement and a strategic pivot to siRNA manufacturing, management ...
Codexis ( (CDXS)) has released its Q3 earnings. Here is a breakdown of the information Codexis presented to its investors. Codexis, Inc. is a biotechnology company specializing in enzymatic solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback